Christopher Reading serves as Executive at HOLLIS EDEN PHARMACEUTICALS INC /DE/, where they oversee executive responsibilities. Since joining the company, Christopher Reading has executed 9 insider transactions totaling $5.2K, demonstrating a bearish approach to their equity position. Their most recent transaction on Feb 16, 2023 involved selling 2,476 shares valued at $15.2K.
Christopher Reading currently holds 37,148 shares of HOLLIS EDEN PHARMACEUTICALS INC /DE/ (HEPH), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Christopher Reading has been a net seller of HEPH stock. They have purchased $0 and sold $5.2K worth of shares.
Christopher Reading's most recent insider trade was on Feb 16, 2023, when they sold 2,476 shares at $6.12 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Feb 14, 2007 | HEPH | $1.0K | Sale | 186 | $5.50 | Discretionary |
| Feb 14, 2007 | HEPH | $1.1K | Sale | 193 | $5.49 | Discretionary |
| Feb 14, 2007 | HEPH | $518 | Sale | 93 | $5.57 | Discretionary |
| Feb 14, 2007 | HEPH | $508 | Sale | 93 | $5.46 | Discretionary |
| Feb 14, 2007 | HEPH | $1.0K | Sale | 186 | $5.52 | Discretionary |
| Feb 14, 2007 | HEPH | $1.0K | Sale | 186 | $5.48 | Discretionary |
| Feb 13, 2006 | HEPH | $0 | Award | 3,750 | $N/A | Discretionary |